Related Experiment Video
Updated: Nov 3, 2025
09:41
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
3.2K
AGMO Inhibitor Reduces 3T3-L1 Adipogenesis
Caroline Fischer1, Annett Wilken-Schmitz1, Victor Hernandez-Olmos2,3,4
1Institute of Clinical Pharmacology, Faculty of Medicine, Goethe University, 60590 Frankfurt, Germany.
Cells
|June 2, 2021
Summary
A novel compound, Cp6, inhibits alkylglycerol monooxygenase (AGMO), an enzyme involved in lipid metabolism. This inhibition affects adipocyte differentiation and lipid droplet accumulation, suggesting AGMO as a potential therapeutic target for metabolic disorders.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Alkylglycerol monooxygenase (AGMO) is a tetrahydrobiopterin (BH4)-dependent enzyme crucial for cleaving alkyl ether glycerolipids.
- AGMO is predominantly expressed in the liver and white adipose tissue, key sites for lipid metabolism.
Purpose of the Study:
- To disclose and biologically characterize a novel AGMO inhibitor, Cp6.
- To investigate the effects of AGMO inhibition on cellular differentiation and lipid storage.
Main Methods:
- Enzyme inhibition assays to determine Cp6's IC50 and selectivity against other BH4-dependent enzymes.
- Cell viability and metabolic activity assays using 3T3-L1 fibroblasts, HepG2 hepatocytes, and RAW264.7 macrophages.
- Assessment of Cp6's impact on 3T3-L1 adipocyte differentiation, lipid droplet accumulation, and macrophage differentiation.
Main Results:
- Cp6 demonstrated potent and selective inhibition of AGMO (IC50: 30-100 µM).
- Cp6 did not affect the viability or metabolic activity of tested cell lines up to 10-fold its IC50.
- Cp6 reversibly inhibited 3T3-L1 adipocyte differentiation, reduced lipid droplet accumulation in adipocytes and HepG2 cells, and impaired M2-like macrophage differentiation.
Conclusions:
- Pharmacologic inhibition of AGMO by Cp6 affects key cellular processes, including adipogenesis and lipid storage.
- AGMO represents a potential therapeutic target for modulating lipid metabolism and related diseases.
- Cp6 serves as a valuable tool for further exploring the biological roles of AGMO.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
345
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
345
01:23Dipeptidyl Peptidase 4 Inhibitors
315
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
315
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.2K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
01:24Glucagon-like Receptor Agonists
509
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
509
01:09GPCRs Regulate Adenylyl Cylase Activity
6.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.2K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.2K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.2K